InvestorsHub Logo
Followers 35
Posts 1393
Boards Moderated 0
Alias Born 09/09/2009

Re: None

Monday, 11/03/2014 10:49:03 AM

Monday, November 03, 2014 10:49:03 AM

Post# of 144814
Malignant ascites: To date, none of the different options has been subjected to evidence-based clinical trials and there are no accepted guidelines for the management of MA.
Do you guys realize that Nuvilex with Hoff's TD2 results could be the first to accomplish a treatment for ascites if the results show a significant reduction in ascites or REMISSION...Nuvilex could be the new GUIDELINE...

http://www.bioportfolio.com/resources/pmarticle/307026/Malignant-ascites-pathophysiology-and-treatment.html


The therapies in this article...."However, NO IMPROVEMENTS IN OVERALL SURVIVAL was observed in any of the clinical trials reported."....we could be the GUIDELINE if we show reduced ascites and improvement in overall survival...

http://www.bioportfolio.com/resources/pmarticle/976526/Malignant-ascites-in-ovarian-cancer-and-the-role-of-targeted-therapeutics.html

bull
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PMCB News